688319.SH
欧林生物
SSE · Healthcare · Biotechnology · CN
CNY 27.82
−7.42%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 774.5M | 704.2M | 588.9M | 496.1M | 547.5M |
| Cost of Revenue | 56.7M | 49.6M | 32.7M | 32.0M | 39.1M |
| Gross Profit | 717.8M | 654.6M | 556.2M | 464.1M | 508.4M |
| Operating Expenses | |||||
| R&D Expense | 124.0M | 132.9M | 134.2M | 114.7M | 122.0M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 72.1M | 75.2M | 86.4M | 78.3M | 63.7M |
| Selling & Marketing Expense | 415.9M | 380.9M | 302.9M | 257.8M | 288.4M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 635.3M | 609.5M | 537.3M | 458.9M | 478.9M |
| Cost and Expenses | 692.0M | 659.1M | 570.0M | 490.9M | 518.0M |
| Operating Income (EBIT) | 70.3M | 30.9M | 21.3M | 3.1M | 41.6M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 71.4M | 31.9M | 22.3M | 15.6M | 43.6M |
| Income Tax Expense | 13.8M | 10.0M | 6.6M | 4.2M | 17.1M |
| Bottom Line | |||||
| Net Income | 56.5M | 22.3M | 20.8M | 17.6M | 26.6M |
| Earnings from Cont. Ops | 56.1M | 21.9M | 15.7M | 11.4M | 26.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 56.5M | 22.3M | 20.8M | 17.6M | 26.6M |
| Per Share | |||||
| Basic EPS | CN¥0.14 | CN¥0.05 | CN¥0.05 | CN¥0.04 | CN¥0.07 |
| Diluted EPS | CN¥0.14 | CN¥0.05 | CN¥0.05 | CN¥0.04 | CN¥0.07 |
| Revenue Per Share | CN¥1.91 | CN¥1.74 | CN¥1.45 | CN¥1.22 | CN¥1.35 |
| Shares | |||||
| Basic Shares Outstanding | 405.2M | 405.5M | 405.4M | 405.4M | 405.1M |
| Diluted Shares Outstanding | 405.2M | 405.5M | 405.4M | 405.4M | 405.1M |
| Profitability Metrics | |||||
| EBITDA | — | 69.7M | 53.6M | 33.4M | 70.3M |
| D&A | — | 38.8M | 32.3M | 30.3M | 28.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026